Lv720
3990 积分 2024-07-23 加入
Apremilast Drug Survival and Tolerability in Real-World Practice
6天前
已关闭
Assessing Predictive Performance of Fibrosis-4 Index in Settings With Lower Prevalence of Liver Fibrosis
6天前
已关闭
Is the combination of resmetirom and semaglutide useful for the treatment of metabolic dysfunction‐associated steatohepatitis?
12天前
已完结
Apremilast, Methotrexate and NB ‐ UVB Phototherapy for Moderate to Severe Psoriasis: Efficacy, Safety, and Immunomodulation in Comparison
21天前
已完结
Non-alcoholic Fatty Liver Disease in Pregnancy: Clinical Implications, Adverse Outcomes, and Therapeutic Considerations
21天前
已完结
Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Facts and Hopes
21天前
已完结
Targeting THR-β for MASLD Treatment: Current Progression and Emerging Prospects
21天前
已完结
SAT-655 Comparative Analysis of Glucagon Receptor Agonists vs Resmetirom in MASLD and MASH:Network Meta-Analysis of Clinical Trials
1个月前
已完结
Meta‐analysis of clinically available pharmacotherapy of biopsy confirmed metabolic dysfunction associated steatohepatitis ( MASH )
1个月前
已完结
Screening and management of metabolic dysfunction-associated steatotic liver disease (MASLD)
1个月前
已完结
皖公网安备34019202002308
